Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission, please carefully check your responses for accuracy; you will not be able to make changes later.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection
Data was collected manually without software or computer code as described in the study protocol.

Data analysis
Data analysis was performed using R (v4.3.1).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data needed to evaluate the conclusions in the paper are present in the manuscript and/or the Supplementary Materials. Data from primary studies are publicly available within the databases listed in Supplementary Information. In case of further questions, please contact the corresponding author.
### Research involving human participants, their data, or biological material

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation, and race, ethnicity and racism.

- Reporting on sex and gender
- Reporting on race, ethnicity, or other socially relevant groupings
- Population characteristics
- Recruitment
- Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

### Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- [x] Life sciences
- [ ] Behavioural & social sciences
- [ ] Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

#### Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Data exclusions</td>
<td>1970 Records excluded (for exclusion reasons, see Fig. 1)</td>
</tr>
<tr>
<td>Replication</td>
<td>If two studies reporting on the same patient population were identified, the study with longer follow-up was chosen.</td>
</tr>
<tr>
<td>Randomization</td>
<td>N/A</td>
</tr>
<tr>
<td>Blinding</td>
<td>N/A</td>
</tr>
</tbody>
</table>

#### Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Study description | |
| Research sample | |
| Sampling strategy | |
| Data collection | |
| Timing | |
| Data exclusions | |
| Non-participation | |
| Randomization | |
Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description
Research sample
Sampling strategy
Data collection
Timing and spatial scale
Data exclusions
Reproducibility
Randomization
Blinding

Did the study involve field work?  Yes  No

Field work, collection and transport

Field conditions
Location
Access & import/export
Disturbance

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

<table>
<thead>
<tr>
<th>n/a</th>
<th>Involved in the study</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>Antibodies</td>
</tr>
<tr>
<td>X</td>
<td>Eukaryotic cell lines</td>
</tr>
<tr>
<td>X</td>
<td>Palaeontology and archaeology</td>
</tr>
<tr>
<td>X</td>
<td>Animals and other organisms</td>
</tr>
<tr>
<td></td>
<td>Clinical data</td>
</tr>
<tr>
<td>X</td>
<td>Dual use research of concern</td>
</tr>
<tr>
<td>X</td>
<td>Plants</td>
</tr>
</tbody>
</table>

Methods

<table>
<thead>
<tr>
<th>n/a</th>
<th>Involved in the study</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>ChIP-seq</td>
</tr>
<tr>
<td>X</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>X</td>
<td>MRI-based neuroimaging</td>
</tr>
</tbody>
</table>

Antibodies

Antibodies used

Validation
**Eukaryotic cell lines**

Policy information about [cell lines and Sex and Gender in Research](#).

- Cell line source(s)
- Authentication
- Mycoplasma contamination
- Commonly misidentified lines (See ICLAC register)

**Palaeontology and Archaeology**

- Specimen provenance
- Specimen deposition
- Dating methods

- Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

**Animals and other research organisms**

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#).

- Laboratory animals
- Wild animals
- Reporting on sex
- Field-collected samples

**Clinical data**

Policy information about [clinical studies](#).

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

- Clinical trial registration: Not a clinical trial. Study was registered with PROSPERO database.
- Study protocol: Study protocol is provided in the supplementary materials (uploaded separately).
- Data collection: Data collection was finished September 7, 2023 (last database search update).
- Outcomes: The primary outcome was NRM (if reported) and the number and causes of death.

**Dual use research of concern**

Policy information about [dual use research of concern](#).

**Hazards**

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:
No | Yes
---|---
☐ Public health
☐ National security
☐ Crops and/or livestock
☐ Ecosystems
☐ Any other significant area

**Experiments of concern**

Does the work involve any of these experiments of concern:

No | Yes
---|---
☐ Demonstrate how to render a vaccine ineffective
☐ Confer resistance to therapeutically useful antibiotics or antiviral agents
☐ Enhance the virulence of a pathogen or render a nonpathogen virulent
☐ Increase transmissibility of a pathogen
☐ Alter the host range of a pathogen
☐ Enable evasion of diagnostic/detection modalities
☐ Enable the weaponization of a biological agent or toxin
☐ Any other potentially harmful combination of experiments and agents

**Plants**

Seed stocks

Novel plant genotypes

Authentication

**ChIP-seq**

**Data deposition**

☐ Confirm that both raw and final processed data have been deposited in a public database such as GEO.

☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

Files in database submission

Genome browser session (e.g. UCSC)

**Methodology**

Replicates

Sequencing depth

Antibodies

Peak calling parameters

Data quality

Software
# Flow Cytometry

## Plots

Confirm that:
- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

## Methodology

<table>
<thead>
<tr>
<th>Sample preparation</th>
<th>Instrument</th>
<th>Software</th>
<th>Cell population abundance</th>
<th>Gating strategy</th>
</tr>
</thead>
</table>

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

- Design type
- Design specifications
- Behavioral performance measures

<table>
<thead>
<tr>
<th>Imaging type(s)</th>
<th>Field strength</th>
<th>Sequence &amp; imaging parameters</th>
<th>Area of acquisition</th>
<th>Diffusion MRI</th>
</tr>
</thead>
</table>

- Used
- Not used

### Preprocessing

- Preprocessing software
- Normalization
- Normalization template
- Noise and artifact removal
- Volume censoring

### Statistical modeling & inference

- Model type and settings
- Effect(s) tested

Specify type of analysis: Whole brain, ROI-based, Both
Statistic type for inference

(See Eklund et al. 2016)

Correction

Models & analysis

n/a | Involved in the study
--- | ---

- [ ] Functional and/or effective connectivity
- [ ] Graph analysis
- [ ] Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis

This checklist template is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/